ES2165042T3 - VACCINE CONTAINING THE VIRUS OF GOAT ARTHRITIS-ENCEPHALITIS AND USE FOR IMMUNOPROTECTION AGAINST HIV-1 INFECTION. - Google Patents

VACCINE CONTAINING THE VIRUS OF GOAT ARTHRITIS-ENCEPHALITIS AND USE FOR IMMUNOPROTECTION AGAINST HIV-1 INFECTION.

Info

Publication number
ES2165042T3
ES2165042T3 ES97916761T ES97916761T ES2165042T3 ES 2165042 T3 ES2165042 T3 ES 2165042T3 ES 97916761 T ES97916761 T ES 97916761T ES 97916761 T ES97916761 T ES 97916761T ES 2165042 T3 ES2165042 T3 ES 2165042T3
Authority
ES
Spain
Prior art keywords
infection
virus
caev
encephalitis
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97916761T
Other languages
Spanish (es)
Inventor
Angeline Douvas
Glenn Ehresmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/616,855 external-priority patent/US5770357A/en
Priority claimed from US08/616,854 external-priority patent/US6033672A/en
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of ES2165042T3 publication Critical patent/ES2165042T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

LA INVENCION SUMINISTRA UNA VACUNA QUE COMPRENDE UN INMUNOGENO DEL VIRUS DE LA ARTRITIS-ENCEFALITIS CAPRINA (CAEV) Y UN EXCIPIENTE FARMACOLOGICAMENTE ACEPTABLE. LA INVENCION TAMBIEN SUMINISTRA UN PROCEDIMIENTO PARA ESTIMULAR UNA RESPUESTA INMUNE EN UN INDIVIDUO CONTRA LA INFECCION POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA 1 O CONTRA LA INFECCION POR EL CAEV MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UN INMUNOGENO DEL CAEV AL INDIVIDUO. LA INVENCION SUMINISTRA ADEMAS UN PROCEDIMIENTO PARA ESTIMULAR UNA RESPUESTA INMUNE IN VITRO MEDIANTE LA PUESTA EN CONTACTO DE UN LIMBOCITO CON UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UN INMUNOGENO DEL CAEV. TAMBIEN SE SUMINISTRAN PROCEDIMIENTOS DE DIAGNOSIS DE LA INFECCION POR CAEV EN HUMANOS.THE INVENTION PROVIDES A VACCINE THAT INCLUDES AN IMMUNOGEN OF THE CAPRINE ARTHRITIS-ENCEPHALITIS VIRUS (CAEV) AND A PHARMACOLOGICALLY ACCEPTABLE EXCIPIENT. THE INVENTION ALSO PROVIDES A PROCEDURE FOR STIMULATING AN IMMUNE ANSWER IN AN INDIVIDUAL AGAINST INFECTION WITH THE VIRUS OF HUMAN IMMUNODEFICIENCY 1 OR AGAINST INFECTION WITH CAEV THROUGH THE ADMINISTRATION OF AN UNFORGUOUSLY EFFECTIVE WARNING AMOUNT. THE INVENTION ALSO PROVIDES A PROCEDURE FOR STIMULATING AN IMMUNE IN VITRO RESPONSE BY PLACING THE CONTACT OF A LIMBOCITO WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF A CAEV IMMUNOGEN. PROCEDURES FOR DIAGNOSIS OF CAEV INFECTION IN HUMANS ARE ALSO SUPPLIED.

ES97916761T 1996-03-15 1997-03-14 VACCINE CONTAINING THE VIRUS OF GOAT ARTHRITIS-ENCEPHALITIS AND USE FOR IMMUNOPROTECTION AGAINST HIV-1 INFECTION. Expired - Lifetime ES2165042T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/616,855 US5770357A (en) 1996-03-15 1996-03-15 Method of diagnosing caprine arthritis-encephalitis virus infection
US08/616,854 US6033672A (en) 1996-03-15 1996-03-15 Method of stimulating an immune response to caprine arthritis-encephalitis virus (CAEV) in humans through the administration of CAEV immunogens

Publications (1)

Publication Number Publication Date
ES2165042T3 true ES2165042T3 (en) 2002-03-01

Family

ID=27087888

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97916761T Expired - Lifetime ES2165042T3 (en) 1996-03-15 1997-03-14 VACCINE CONTAINING THE VIRUS OF GOAT ARTHRITIS-ENCEPHALITIS AND USE FOR IMMUNOPROTECTION AGAINST HIV-1 INFECTION.

Country Status (12)

Country Link
EP (1) EP0910405B1 (en)
JP (1) JP2002503205A (en)
CN (1) CN1236818C (en)
AT (1) ATE207364T1 (en)
AU (1) AU732865B2 (en)
DE (1) DE69707680T2 (en)
DK (1) DK0910405T3 (en)
ES (1) ES2165042T3 (en)
HK (1) HK1021133A1 (en)
PT (1) PT910405E (en)
RU (1) RU2194529C2 (en)
WO (1) WO1997033615A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602505B2 (en) 1998-04-30 2003-08-05 University Of Southern California Viral chimeras comprised of CAEV and HIV-1 genetic elements
AU2002353346A1 (en) * 2002-09-10 2004-04-30 Samir Chachoua Induced remission therapy
CN107488219A (en) * 2017-08-07 2017-12-19 新疆畜牧科学院 A kind of Caprine arthritis encephalitis virus serum antibody diagnostic flag albumen gp135 and preparation method thereof
CN107632153B (en) * 2017-08-07 2019-05-24 新疆畜牧科学院 A kind of small ruminant slow virus indirect ELISA testing kit

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2721618B1 (en) * 1994-06-28 1996-09-13 Centre Nat Rech Scient Nucleic acid fragments and corresponding peptide fragments from the genome of the caprine arthritis and encephalitis virus (VAEC) and their applications.
FR2732346B1 (en) * 1995-03-27 1997-05-30 Centre Nat Rech Scient MUTE PROTEINS, ENCODED BY LENTIVIRUS MUTE GENES, PEPTIDE FRAGMENTS INCLUDED IN SAID PROTEINS, EXPRESSION VECTORS EXPRESSING MUTE PROTEINS AND THEIR APPLICATIONS

Also Published As

Publication number Publication date
HK1021133A1 (en) 2000-06-02
PT910405E (en) 2002-03-28
EP0910405A2 (en) 1999-04-28
DE69707680D1 (en) 2001-11-29
AU2529797A (en) 1997-10-01
JP2002503205A (en) 2002-01-29
AU732865B2 (en) 2001-05-03
CN1236818C (en) 2006-01-18
EP0910405B1 (en) 2001-10-24
ATE207364T1 (en) 2001-11-15
WO1997033615A3 (en) 1998-03-05
WO1997033615A2 (en) 1997-09-18
RU2194529C2 (en) 2002-12-20
DK0910405T3 (en) 2002-02-18
CN1219881A (en) 1999-06-16
DE69707680T2 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
DK239782A (en) Capsules CONTAINING THE ACTIVE PRINCIPLE OF AN ALLERGY AND PROCEDURE FOR PREPARING IT
ES2176232T3 (en) ADEQUATE VACCINE TO BE USED IN THE PREVENTION AND TREATMENT OF INFECTION WITH HELICOBACTER.
CO4980846A1 (en) A PHARMACEUTICAL COMPOSITION USED IN A METHOD FOR THE PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
ES2104556T3 (en) PEPTIDES THAT HAVE IMMUNOLOGICAL PROPERTIES OF HIV-2.
AR032597A1 (en) USE OF ANTIGENS OF THE VIRUS OF THE INACTIVATED FLU, IN THE PREPARATION OF VACCINES OF A SINGLE INTRANASAL DOSE; METHOD FOR THE PROPHYLAXIS OF DISEASES OR OF INFLUENCES IN PATIENTS; EQUIPMENT THAT INCLUDES SUCH VACCINES IN SINGLE DOSE AND METHOD FOR MANUFACTURING VACCINES FOR THE FLU FOR APLI
MX9304837A (en) PEPTIDES ABLE TO INHIBIT THE ACTIVITY OF HIV PROTEASE, ITS PREPARATION AND ITS THERAPEUTIC USE.
MX9308005A (en) HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITING COMPOUNDS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM.
ES2165042T3 (en) VACCINE CONTAINING THE VIRUS OF GOAT ARTHRITIS-ENCEPHALITIS AND USE FOR IMMUNOPROTECTION AGAINST HIV-1 INFECTION.
MX9308025A (en) HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITING COMPOUNDS, PROCEDURE FOR SUPREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM.
AR003941A1 (en) HIV-1 NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
NO981898D0 (en) Use of flupirtine for the prevention and treatment of diseases associated with damage to the hematophotic cell system
ES2137378T3 (en) POLYAMAMIFIED PEPTIDIC STRUCTURES TO BE USED AGAINST HIV.
DK56389A (en) PREVENTION AND TREATMENT OF RETROVIRAL DISEASES
ATE108335T1 (en) KIT OR COMPOSITION FOR THE PREVENTION OR TREATMENT OF HIV-1 INFECTION.
HUP0100937A2 (en) Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
CA2249736A1 (en) Caprine arthritis-encephalitis virus provides immunoprotection against hiv-1 infection
DE69922642D1 (en) VIRAL CHIMERS FROM CAEV AND HIV-1 GENETIC ELEMENTS
AR027738A1 (en) COMPOSITION COADYUVANTE, COMPOSITIONS OF VACCINES THAT INCLUDE SUCH COMPOSITION COADYUVANTE; PROCEDURE FOR INDUCTION OF IMMUNE IMMUNORESPUESTAS AMMAMIFEROS AND PROCEDURE OF TREATMENT WHERE SUCH VACCINES APPLY
DK0545991T3 (en) Peptides that block human immunodeficiency virus infections, and methods for their use
EA199700353A1 (en) Compositions and methods for detecting and treating acquired immunodeficiency syndrome
CO2022016537A2 (en) Inactivated vaccine for sars-cov-2 and preparation thereof
WO2022150719A3 (en) Antigenic composition(s) and method(s) against porphyromonas gingivalis for the prevention and/or treatment of infection and/or diseases
CR20220313A (en) IMMEDIATE RELEASE PEDIATRIC FORMULATION OF POTASSIUM CANAL OPENER EZOGABINE
IT7821559A0 (en) PERFECTED INDIVIDUAL ENDOOSSEOUS IMPLANT FOR ODONTOSTOMATOLOGY (MOUTH SURGERY) AND PROCEDURE FOR ITS QUICK AND PERFECT APPLICATION ON THE PATIENT.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 910405

Country of ref document: ES